Russian plant inspections will cost foreign drugmakers $38,000

16 February 2016

Up to 3 million roubles (~$38,000) will be paid by foreign pharmaceutical companies, supplying their drugs to the Russian market, for the inspections of their plants by Russian inspectors, according to recent calculations of the Russian Ministry of Health.

It is planned that inspections will be carried out in accordance with the Russian legislation and will be conducted by the experts of the Russian State Institute for Drugs and Good Practices (RSIDGP), reports The Pharma Letter’s local correspondent.

According to recent statements of the Russian Ministry of Health, starting from January 1, 2016, foreign pharmaceutical companies cannot register their new drugs in Russia unless their quality standards conform to the Russian quality standards, based on Good Manufacturing Practice (GMP) requirements.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK